Technology evaluation: MLN-591, Cornell University/BZL Biologics/ImmunoGen/Millennium.
MLN-591 is a monoclonal antibody specific for prostate-specific membrane antigen that is being developed by Cornell University, BZL Biologics, ImmunoGen Inc and Millennium Pharmaceuticals Inc for the potential treatment of prostate cancer. MLN-591 was in phase II trials by May 2002.
Doehn
Christian
C
Department of Urology, University of Lübeck Medical School, Ratzeburger Allee 160, 23538 Lübeck, Germany. doehn@medinf.mu-luebeck.de
Jocham
Dieter
D
D000818:Animals; D000954:Antigens, Surface; D002268:Carboxypeptidases / Q000037:antagonists & inhibitors / Q000276:immunology / Q000378:metabolism*; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D016503:Drug Delivery Systems / Q000379:methods; D004341:Drug Evaluation / Q000331:legislation & jurisprudence / Q000379:methods; D043425:Glutamate Carboxypeptidase II; D006801:Humans; D008297:Male; D013678:Technology, Pharmaceutical / Q000331:legislation & jurisprudence / Q000379:methods*
D000954:Antigens, Surface; D002268:Carboxypeptidases; C473848:FOLH1 protein, human; D043425:Glutamate Carboxypeptidase II